Form 8-K CAPRICOR THERAPEUTICS, For: Feb 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Supermicro probe finds no senior management link to export violations
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
Capricor (CAPR) Receives FDA RMAT Designation for Duchenne Muscular Dystrophy Therapy
February 5, 2018 7:09 AM ESTCapricor Therapeutics (NASDAQ: CAPR) today announced that the U.S. Food and Drug Administration (FDA) has granted CAP-1002, its lead investigational cell therapy for the treatment of Duchenne muscular dystrophy, the Regenerative Medicine Advanced Therapy (RMAT) designation.
In notifying Capricor, the FDA Office of Tissues and Advanced Therapies, stated that the FDA will work closely with Capricor to provide guidance on the subsequent development of CAP-1002 for the treatment of Duchenne muscular dystrophy, including providing advice on generating the evidence needed to support approval of the drug in an efficient manner.
The FDA... More
